-
-
18+Age Range
-
Active, Not Recruiting
Active, Not Recruiting
Safety Study of Abatacept to Treat Rheumatoid Arthritis (B)
The purpose of this study is to compare the incidence rates of targeted infections, malignancies and mortality among patients with rheumatoid arthritis who are treated with abatacept and those who are treated with other anti-rheumatic medications.
Inclusion Criteria: - Signed informed consent - Diagnosis of rheumatoid arthritis - > 18 years at index treatment initiation or switch - Starting treatment with abatacept or new disease-modifying anti-rheumatic drug (including switching or adding) or biologic disease modifying drug. - Read/write English Exclusion Criteria: - None
Patients with rheumatoid arthritis initiating abatacept
Pts w/ RA non-biologic disease-modifying anti-rheumatic drugs
Pts with RA initiating other biologic disease-modifying drugs
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information